Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 15/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982033 | 0.84 | KDM4E (0.44) | KDM4EALDH1A1HPGDPTGS2PTGS1 | |
| SCHEMBL212954 | 0.79 | KDM4E (0.57) | KDM4EALDH1A1HPGDPTGS2PTGS1 | |
| SCHEMBL10512942 | 0.79 | KDM4E (0.43) | KDM4EALDH1A1HPGDPTGS2PTGS1 | |
| SCHEMBL10597711 | 0.78 | KDM4E (0.42) | KDM4EALDH1A1HPGDPTGS2PTGS1 | |
| SCHEMBL6093316 | 0.77 | PTGS2 (0.65) | PTGS2PTGS1 | |
| SCHEMBL27916566 | 0.77 | PTGS2 (0.65) | PTGS2PTGS1 | |
| SCHEMBL4751105 | 0.77 | PTGS2 (0.65) | PTGS2PTGS1 | |
| SCHEMBL5794328 | 0.77 | KDM4E (0.44) | KDM4EALDH1A1HPGDPTGS2PTGS1 | |
| SCHEMBL1772589 | 0.76 | KDM4E (0.43) | KDM4EALDH1A1HPGDPTGS2PTGS1 | |
| SCHEMBL6212296 | 0.76 | KDM4E (0.43) | KDM4EALDH1A1HPGDPTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | claimed |
| CN-103880827-A | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RES INC | 2014-06-25 | — | — | CN | disclosed |
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | KDM4E 2673/4885ALDH1A1 1554/4885HPGD 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.